Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants

Schulzke, Sven; Kaempfen, Sirée; Patole, Sanjay

doi:10.1002/14651858.cd010018.pub2

Cited by 12 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTX competitively inhibits phosphodiesterases in a range of cells and tissues, thereby increasing intracellular cAMP, a second messenger which acts via protein kinase A to suppress gene transcription of proinflammatory mediators including tumor necrosis factor (TNF) (5,6). Due to its anti-TNF activity, PTX has been studied in animals and human adults and newborns to ameliorate inflammatory conditions such as sepsis, BPD, meconium aspiration, and hypoxic ischemic encephalopathy (7)(8)(9)(10)(11). Adverse reactions of PTX in adults include gastrointestinal and CNS symptoms, whereas significant adverse reactions at therapeutic doses are rare in adults (www.pdr.net/drug-summary/Pentoxifylline, www.fda.…”

mentioning

confidence: 99%

Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns

et al. 2017

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns

et al. 2017

View full text Add to dashboard Cite

show abstract

“…There were, however, methodological weaknesses in the RCT including the assessors were not blinded to treatment group and there was complete outcome reporting in only 65% of those recruited [77]. When the data were analysed on an intention to treat basis the differences no longer reached statistical significance [78]. A subsequent RCT of 80 infants with a gestational age less than 28 weeks, with more robust blinding and 100% outcome data, did not show a statistically significant difference in the incidence of BPD or the total duration of oxygen therapy (p=0.75) [79].…”

Section: Pentoxifyllinementioning

confidence: 99%

Advances in emerging treatment options to prevent bronchopulmonary dysplasia

Ling

Greenough

2017

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

Introduction: Bronchopulmonary dysplasia (BPD) is common sequaelae of premature birth.It can be complicated by the development of pulmonary hypertension (PH), which significantly increases mortality. Areas covered: The aim of this review is to evaluate emerging drug therapies for prevention and treatment of BPD and associated PH. These include superoxide dismutase, macrolides, Clara secretary cell protein, -1 protease inhibitors, pentoxifylline, melatonin, inositol, N-acetyl cysteine, allopurinol, cimetidine, pulmonary vasodilators and mesenchymal stem cells (MSC). We have also included discussion on longer standing therapies such as corticosteroids, caffeine and vitamin A.Expert opinion: Corticosteroid administration systemically, but not by inhalation, caffeine and vitamin A reduce BPD. Enhancing endogenous anti-oxidant mechanisms through supplementation with superoxide dismutase or Clara cell secretory protein has yielded encouraging results. Azithromycin, a macrolide used to treat Ureaplasma infection, also has anti-inflammatory properties and has been shown to reduce BPD. Sildenafil reduces the echocardiographic markers of pulmonary hypertension associated with BPD, but has not been shown to prevent BPD. In animal models and a small phase one study MSC administration has resulted in promising results. Appropriately powered studies with long term outcomes are required to assess the efficacy of all these treatments.3

show abstract

“…Pentoxifylline is another nonselective PDE inhibitor that can be potentially beneficial in BPD . In addition to anti‐inflammatory properties, it lowered blood viscosity and improved microcirculation and tissue perfusion, with rare adverse effects .…”

Section: Respiratory Distress In the Neonatesmentioning

confidence: 99%

Phosphodiesterase inhibitors: Potential role in the respiratory distress of neonates

Mokrá

Mokrý

Matasová

2018

Pediatric Pulmonology

View full text Add to dashboard Cite

Phosphodiesterases (PDEs) are a superfamily of enzymes that catalyze the hydrolysis of phosphodiester bonds of 3',5' cyclic adenosine and guanosine monophosphate (cAMP and cGMP). PDEs control hydrolysis of cyclic nucleotides in many cells and tissues. Inhibition of PDEs by selective or nonselective PDE inhibitors represents an effective targeted strategy for the treatment of various diseases including respiratory disorders. Recent data have demonstrated that PDE inhibitors can also be of benefit in respiratory distress in neonates. This article outlines the pharmacological properties of nonselective and selective PDE inhibitors and provides up-to-date information regarding their use in experimental models of neonatal respiratory distress as well as in clinical studies.

show abstract

Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants

Cited by 12 publications

References 44 publications

Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns

Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns

Advances in emerging treatment options to prevent bronchopulmonary dysplasia

Phosphodiesterase inhibitors: Potential role in the respiratory distress of neonates

Contact Info

Product

Resources

About